

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) ~~An Akt-inhibiting polypeptide specifically inhibiting Akt activity, which consists of~~ consisting of: a peptide having an amino acid sequence indicated in SEQ ID NO: 1, 3, 5, 7 or 9 of the sequence listing.
2. (Currently Amended) ~~An Akt-inhibiting polypeptide consisting of~~ consisting of: a peptide having an amino acid sequence ~~wherein one or several amino acids are deleted, substituted or added in the amino acid sequence~~ indicated in SEQ ID NO: 1, 3, 5, 7 or 9 of the sequence listing, wherein one or several amino acids are deleted, substituted or added in the amino acid sequence and specifically inhibiting Akt activity.
3. (Currently Amended) A polynucleotide encoding an Akt-inhibiting polypeptide, the polypeptide consisting of gene DNA encoding a following protein (a) or (b):  
(a) ~~a polypeptide consisting of~~ peptide having an amino acid sequence indicated in SEQ ID NO: 1, 3, 5, 7 or 9 of the sequence listing; or  
(b) ~~a polypeptide consisting of a peptide an amino acid sequence~~ wherein one or several amino acids are deleted, substituted or added in the amino acid sequence indicated in SEQ ID NO: 1, 3, 5, 7 or 9 of the sequence listing, and specifically inhibiting Akt activity.

4. (Currently Amended) A polynucleotide encoding an Act-inhibiting polypeptide, the polynucleotide consisting part or whole of DNA consisting of a base sequence indicated in SEQ ID NO: 2, 4, 6, 8, or 10 of the sequence listing; or part or whole of these sequences, and encoding a polypeptide that specifically inhibits Akt activity.
5. (Currently Amended) A polynucleotide consisting of: a DNA base sequence that hybridizes with the polynucleotide of DNA hybridizing with the DNA according to claim 4 under stringent conditions, and encoding a polypeptide that specifically inhibits Akt activity.
6. (Currently Amended) A recombinant expression vector, comprising:  
a gene expression vector, and  
~~which is constructed by integrating~~ a DNA encoding the polypeptide that specifically inhibits Akt activity according to any one of claims 3-5 integrated into [[a]] the gene expression vector.
7. (Currently Amended) A method for producing a polypeptide that specifically inhibits Akt activity, comprising: introducing wherein the recombinant expression vector according to claim 6 is introduced into a host cell; and expressed expressing the recombinant expression vector.
8. (Original) An antibody which is induced by using a polypeptide indicated in SEQ ID NO: 1, 3, 5, 7 or 9 of the sequence listing and specifically binds to the polypeptide.
9. (Original) The antibody according to claim 8 wherein the antibody is a monoclonal antibody.

10. (Original) The antibody according to claim 8 wherein the antibody is a polyclonal antibody.
11. (Currently Amended) A specific inhibitor of Akt activity, comprising: ~~wherein the~~ polypeptide according to claim 1 or 2 ~~[[is]]~~ as an active ingredient.
12. (Currently Amended) The specific inhibitor of Akt activity according to claim 11, wherein the polypeptide is a sequence of an amino acid residue 10-24 of an amino acid sequence for human TCL1 protein.
13. (Currently Amended) The specific inhibitor of Akt activity according to claim 11, wherein the polypeptide is a sequence of an amino acid residue 8-22 of an amino acid sequence for human TCL1B protein.
14. (Currently Amended) The specific inhibitor of Akt activity according to claim 11, wherein the polypeptide is a sequence of an amino acid residue 5-19 of an amino acid sequence for human MTP1 protein.
15. (Currently Amended) The specific inhibitor of Akt activity according to claim 11, wherein the polypeptide is a sequence of an amino acid residue 9-24 of an amino acid sequence for mouse TCL1 protein.
16. (Currently Amended) The specific inhibitor of Akt activity according to claim 11, wherein the polypeptide is a sequence of an amino acid residue 9-24 of an amino acid sequence for rat MTP1 protein.

17. (Currently Amended) The specific inhibitor of Akt activity according to ~~any one of~~ claims 11 ~~[[16]]~~, wherein specific inhibition of Akt activity is the inhibition of binding of phosphoinositide to Akt.
18. (Currently Amended) An antitumor agent comprising ~~wherein~~ the polypeptide according to claim 1 or 2 ~~[[is]]~~ as an active ingredient.
19. (Original) The antitumor agent according to claim 18, wherein the antitumor agent is an agent for prevention or treatment of malignancy.
20. (Original) The antitumor agent according to claim 19, wherein treatment of malignancy is prevention or treatment of breast cancer, lung cancer, leukemia or lymphoid tumor.
21. (Currently Amended) A method for ~~specifically~~ inhibiting Akt activity, comprising:  
[[by]] introducing the polynucleotide ~~a DNA encoding the polypeptide that~~  
~~specifically inhibits Akt activity~~ according to any one of claims 3-5 into living cells to express the polypeptide that specifically inhibits Akt activity.